Trial Profile
An effect of short-term treatment with fingolimod on redistribution of natural killer cell in patients with multiple sclerosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 26 Feb 2016 New trial record